| Drs Tucker Kudrna Holec Eyecare Cen | |
| 2020 Jackson Blvd 1, Rapid City, South Dakota 57702 | |
| (605) 342-0777 |
| Name | Drs Tucker Kudrna Holec Eyecare Cen |
|---|---|
| Organization Name | Drs Tucker-kudrna-holec-young Eyecare Centre Llp |
| Location | 2020 Jackson Blvd 1, Rapid City, South Dakota 57702 |
| Type | Supplier |
| Phone | (605) 342-0777 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Researchers from the Higher School of Economics conducted a meta-analysis by compiling data across 17 neuroimaging studies on working memory in children.
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved a new indication for MICARDIS® (telmisartan) for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. MICARDIS® is the first treatment in its class to be approved for this indication.
Nuevolution A/S today announced that it has entered into a scientific collaboration with Duke University, the Howard Hughes Medical Institute, and Lexicon Pharmaceuticals, Inc. for the investigation of the biological mechanism of action of a specified GPCR drug target.
A half dozen University of Connecticut researchers are now working to identify potential new drugs to treat a wide range of diseases and conditions through a unique partnership that offers access to cutting-edge artificial intelligence technology and screening compounds at no cost.
› Verified 1 days ago
News Archive
Researchers from the Higher School of Economics conducted a meta-analysis by compiling data across 17 neuroimaging studies on working memory in children.
Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) has approved a new indication for MICARDIS® (telmisartan) for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. MICARDIS® is the first treatment in its class to be approved for this indication.
Nuevolution A/S today announced that it has entered into a scientific collaboration with Duke University, the Howard Hughes Medical Institute, and Lexicon Pharmaceuticals, Inc. for the investigation of the biological mechanism of action of a specified GPCR drug target.
A half dozen University of Connecticut researchers are now working to identify potential new drugs to treat a wide range of diseases and conditions through a unique partnership that offers access to cutting-edge artificial intelligence technology and screening compounds at no cost.
› Verified 1 days ago
Apria Healthcare Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 821 Mount Rushmore Rd, Rapid City, South Dakota 57701 Phone: (605) 341-2273 | |
Partner Medical Home Care Rc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 403 West Blvd, Rapid City, South Dakota 57701 Phone: (605) 342-2773 | |
Lincare Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 518 5th St, Rapid City, South Dakota 57701 Phone: (605) 342-3890 | |
Cvs Pharmacy #17510 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1415 Eglin St, Rapid City, South Dakota 57701 Phone: (605) 341-8621 | |
Walgreens #5643 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 540 Mountain View Rd, Rapid City, South Dakota 57702 Phone: (605) 342-6010 |